Delivering freedom from chronic skin disease
At Oruka, our novel biologics target the core mechanisms underlying psoriasis and other conditions. We aim to improve on current treatments to help people experience the greatest possible freedom from disease. To us, that means delivering the highest possible rates of disease clearance while requiring the fewest number of doses.
Raising the standard of care for psoriasis and beyond
Psoriasis is a chronic autoimmune skin disorder characterized by inflammation that manifests as itchy, painful plaques and scales on the skin. It affects an estimated 125 million people worldwide. One in three develop psoriatic arthritis, which can lead to joint pain and stiffness and permanent joint damage. Patients with psoriasis are at greater risk of developing other conditions, such as obesity, diabetes, cardiovascular disease, and depression.
At Oruka, we are advancing a new era of biologics with the potential to enable higher rates of complete skin clearance, durable remissions, and more convenient dosing regimens for patients around the globe.
Deep expertise fueling best-in-class therapies
Our team comprises world-class drug developers, company builders, and strategists with deep biopharma experience and a passion for improving the standard of care.
- Leadership Team
- Board Of Directors
Lawrence Klein, PhD
Chief Executive Officer
Joana Goncalves, MBChB
Chief Medical Officer
Paul Quinlan, JD, LLM
General Counsel
Laura Sandler
SVP, Operations
Arjun Agarwal
SVP, Finance
Christopher Finch
VP, Corporate Development & Strategy
Alan Lada
VP, Investor Relations
Eugenia Levi, PharmD
VP, Medical Affairs
Rajiv Panwar
VP, Head of CMC
Joe Senn, PhD
SVP, Nonclinical R&D
Jeremy Slessman
VP, Quality
Andrew Blauvelt, MD, MBA
Chair, Scientific Advisory Board